Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion

Open access
Brousseau, Margaret E., Diffenderfer, Margaret R., Millar, John S., Nartsupha, Chorthip, Asztalos, Bela F., Welty, Francine K., Wolfe, Megan L., Rudling, Mats, Björkhem, Ingemar, Angelin, Bo, Mancuso, James P., Digenio, Andres G., Rader, Daniel J., Schaefer, Ernst J.·2005·Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Objective— Pharmacological inhibition of the cholesteryl ester transfer protein (CETP) in humans increases high-density lipoprotein (HDL) cholesterol (HDL-C) levels; however, its effects on apolipoprotein A-I (apoA-I) containing HDL subspecies, apoA-I turnover, and markers of reverse cholesterol transport are unknown. The present study was designed to address these issues. Methods and Results— Nineteen subjects, 9 of whom were taking 20 mg of atorvastatin for hypercholesterolemia, received placebo for 4 weeks, followed by the CETP inhibitor torcetrapib (120 mg QD) for 4 weeks. In 6 subjects from the nonatorvastatin cohort, the everyday regimen was followed by a 4-week period of torcetrapib (120 mg BID). At the end of each phase, subjects underwent a primed-constant infusion of (5,5,5- 2 H 3 )- l -leucine to determine the kinetics of HDL apoA-I. The lipid data in this study have been reported previously. Relative to placebo, 120 mg daily torcetrapib increased the amount of apoA-I in α1-migrating HDL in the atorvastatin (136%; P <0.001) and nonatorvastatin (153%; P <0.01) cohorts, whereas an increase of 382% ( P <0.01) was observed in the 120 mg twice daily group. HDL apoA-I pool size increased by 8±15% in the atorvastatin cohort ( P =0.16) and by 16±7% ( P <0.0001) and 34±8% ( P <0.0001) in the nonatorvastatin 120 mg QD and BID cohorts, respectively. These changes were attributable to reductions in HDL apoA-I fractional catabolic rate (FCR), with torcetrapib reducing HDL apoA-I FCR by 7% ( P =0.10) in the atorvastatin cohort, by 8% ( P <0.001) in the nonatorvastatin 120 mg QD cohort, and by 21% ( P <0.01) in the nonatorvastatin 120 mg BID cohort. Torcetrapib did not affect HDL apoA-I production rate. In addition, torcetrapib did not significantly change serum markers of cholesterol or bile acid synthesis or fecal sterol excretion. Conclusions— These data indicate that partial inhibition of CETP via torcetrapib in patients with low HDL-C: (1) normalizes apoA-I levels within α1-migrating HDL, (2) increases plasma concentrations of HDL apoA-I by delaying apoA-I catabolism, and (3) does not significantly influence fecal sterol excretion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000161928.16334.dd

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 233

Metadata

Authors
Brousseau, M. E., Diffenderfer, M. R., Millar, J. S., Nartsupha, C., Asztalos, B. F., Welty, F. K., Wolfe, M. L., Rudling, M., Björkhem, I., Angelin, B., Mancuso, J. P., Digenio, A. G., Rader, D. J., & Schaefer, E. J.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2005-05
Volume
25
Issue
5
Pages
1057-1064
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2134930063
Cited by
233
References
7
FWCI
32.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion. https://app.cochat.ai/papers/10.1161/01.atv.0000161928.16334.dd
The paper
Brousseau, M. E., Diffenderfer, M. R., Millar, J. S., Nartsupha, C., Asztalos, B. F., Welty, F. K., Wolfe, M. L., Rudling, M., Björkhem, I., Angelin, B., Mancuso, J. P., Digenio, A. G., Rader, D. J., & Schaefer, E. J. (2005). Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.0000161928.16334.dd

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.